{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:12:28Z","timestamp":1788577948852,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01816"],"award-info":[{"award-number":["PI22\/01816"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["DTS23\/00114"],"award-info":[{"award-number":["DTS23\/00114"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018780","name":"Government of Andalusia Andalusian Health Service","doi-asserted-by":"publisher","award":["RC\\u22120009\\u20132021"],"award-info":[{"award-number":["RC\\u22120009\\u20132021"]}],"id":[{"id":"10.13039\/501100018780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018780","name":"Government of Andalusia Andalusian Health Service","doi-asserted-by":"publisher","award":["SA 0263\/2017"],"award-info":[{"award-number":["SA 0263\/2017"]}],"id":[{"id":"10.13039\/501100018780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"Caixabank SA","doi-asserted-by":"publisher","award":["CI25\\u201320197"],"award-info":[{"award-number":["CI25\\u201320197"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","award":["PRYES247250BARR"],"award-info":[{"award-number":["PRYES247250BARR"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017642","name":"National Plan for Scientific and Technical Research and Innovation","doi-asserted-by":"publisher","award":["CNS2023\\u2013145629"],"award-info":[{"award-number":["CNS2023\\u2013145629"]}],"id":[{"id":"10.13039\/501100017642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017642","name":"National Plan for Scientific and Technical Research and Innovation","doi-asserted-by":"publisher","award":["JDC2023\\u2013050934-I"],"award-info":[{"award-number":["JDC2023\\u2013050934-I"]}],"id":[{"id":"10.13039\/501100017642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.semcancer.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:07:26Z","timestamp":1785251246000},"page":"75-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis"],"prefix":"10.1016","volume":"125","author":[{"given":"Marilina","family":"Garc\u00eda-Aranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zafra-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Rodr\u00edguez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semcancer.2026.07.004_bib1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.07.004_bib2","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijrobp.2025.06.1121","article-title":"Treatment with stereotactic ablative radiotherapy for up to five oligometastases in patients with cancer: long-term outcomes of the nonrandomized phase 2 SABR-5 clinical trial","volume":"123","author":"Leclerc","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"25","key":"10.1016\/j.semcancer.2026.07.004_bib3","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10422","key":"10.1016\/j.semcancer.2026.07.004_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(23)02351-6","article-title":"SBRT for oligoprogressive disease: using the evidence to maximise the benefits","volume":"403","author":"Hanna","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semcancer.2026.07.004_bib5","first-page":"19","article-title":"Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation","volume":"5","author":"Reese","year":"2013","journal-title":"Mol. Cell. Pharmacol."},{"key":"10.1016\/j.semcancer.2026.07.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111016","article-title":"Cancer evolution: A means by which tumors evade treatment","volume":"133","author":"Zhu","year":"2021","journal-title":"Biomed. & Pharmacother."},{"issue":"7","key":"10.1016\/j.semcancer.2026.07.004_bib7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2026.07.004_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.semcancer.2026.07.004_bib9","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2014"},{"issue":"5","key":"10.1016\/j.semcancer.2026.07.004_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.semcancer.2026.07.004_bib11","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO-25-00131","article-title":"Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: The RAVENS phase II randomized trial","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2026.07.004_bib12","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.3390\/ijms25084533","article-title":"Novel blood biomarkers for response prediction and monitoring of stereotactic ablative radiotherapy and immunotherapy in metastatic oligoprogressive lung cancer","volume":"25","author":"Zafra","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.semcancer.2026.07.004_bib13","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1158\/1078-0432.CCR-21-2510","article-title":"Phase II evaluation of stereotactic ablative radiotherapy (SABR) and immunity in 11C-Choline-PET\/CT\u2013Identified Oligometastatic Castration-Resistant Prostate Cancer","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2026.07.004_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.radonc.2016.03.014","article-title":"Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan","volume":"119","author":"Dubois","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.07.004_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijrobp.2018.09.001","article-title":"Prospective immunophenotyping of CD8+ T cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed SBRT","volume":"103","author":"Evans","year":"2019","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"16","key":"10.1016\/j.semcancer.2026.07.004_bib16","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/pros.24787","article-title":"Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy","volume":"84","author":"Matrone","year":"2024","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.semcancer.2026.07.004_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-025-04218-6","article-title":"Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients","volume":"75","author":"Oliver","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"10422","key":"10.1016\/j.semcancer.2026.07.004_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2026.07.004_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108722","article-title":"Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy","author":"Guijosa","year":"2025","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2026.07.004_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-021-08228-2","article-title":"Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non\u2013small-cell lung cancer: a propensity-matched retrospective study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2026.07.004_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2022.11.006","article-title":"Genomic and transcriptomic predictors of response from stereotactic body radiation therapy in patients with oligoprogressive renal cell carcinoma","volume":"6","author":"Zengin","year":"2023","journal-title":"Eur. Urol. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2026.07.004_bib22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ijrobp.2024.07.2336","article-title":"Is local ablative stereotactic radiation therapy a valuable rescue strategy for time on drug in patients enrolled in phase I trials?","volume":"120","author":"Mavrikios","year":"2024","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"15","key":"10.1016\/j.semcancer.2026.07.004_bib23","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1002\/cam4.4068","article-title":"Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer","volume":"10","author":"Wijetunga","year":"2021","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.semcancer.2026.07.004_bib24","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1038\/s41598-025-88266-z","article-title":"Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases","volume":"15","author":"Radigan","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2026.07.004_bib25","article-title":"Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily-pretreated Metastatic Osteosarcoma","author":"Zhu","year":"2025","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"5","key":"10.1016\/j.semcancer.2026.07.004_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ijrobp.2022.12.006","article-title":"WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer","volume":"115","author":"Sutera","year":"2023","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"4","key":"10.1016\/j.semcancer.2026.07.004_bib27","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.21037\/jgo-2025-100","article-title":"Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival","volume":"16","author":"Elhariri","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.07.004_bib28","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2022.05.037","article-title":"Tumor-derived extracellular vesicles predict clinical outcomes in oligometastatic prostate cancer and suppress antitumor immunity","volume":"114","author":"Lucien","year":"2022","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"key":"10.1016\/j.semcancer.2026.07.004_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02856","article-title":"Addition of metastasis-directed therapy to standard of care for oligometastatic solid tumors: primary analysis of all tumor-histology baskets of the phase II randomized EXTEND trial","author":"Sherry","year":"2026","journal-title":"J. Clin. Oncol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:23:45Z","timestamp":1788575025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X26000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S1044579X26000738"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.07.004","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}